What is CorneaGen?
CorneaGen operates as a premier eye bank, functioning as a critical node in the supply chain for corneal transplant procedures. The company distinguishes itself by integrating the distribution of high-quality donor corneal tissue with the provision of proprietary surgical instruments. This dual-pronged approach allows ophthalmologists to achieve superior clinical outcomes, effectively addressing the complexities of corneal disease management. With a widespread network of facilities and strategic partnerships across the United States, CorneaGen serves as a vital intermediary in the restoration of vision, prioritizing both the quality of biological assets and the efficacy of the tools utilized in modern surgical environments.
How much funding has CorneaGen raised?
CorneaGen has raised a total of $42M across 2 funding rounds:
Series A
$5M
Series B
$37M
Series A (2018): $5M, investors not publicly disclosed
Series B (2020): $37M led by Flying L Partners
Key Investors in CorneaGen
Flying L Partners
A private investment firm focused on providing growth capital to companies within the healthcare and medical services sectors.
Undisclosed Investor
An undisclosed investor participating in the funding round, providing strategic liquidity to support long-term organizational objectives.
What's next for CorneaGen?
With the recent influx of capital, CorneaGen is well-positioned to accelerate its operational footprint and enhance its technological offerings. The company is expected to focus on scaling its logistics network to ensure the rapid, safe delivery of transplant tissues, while simultaneously investing in the research and development of next-generation surgical instruments. As the demand for advanced ophthalmic care rises, CorneaGen's strategic roadmap likely includes expanding its educational initiatives for surgeons and deepening its integration within the broader healthcare ecosystem. This phase of development will be pivotal in maintaining its market leadership and ensuring that the gift of sight remains accessible through innovation and operational excellence.
See full CorneaGen company page
